
Australia's largest biotech company plans to expand its US presence with a $US1.5 billion ($A2.3 billion) investment that will allow it to manufacture more therapies derived from blood plasma collected in the states.
The funds injection could also potentially help CSL avoid or mitigate any future pharmaceutical tariffs imposed by US President Donald Trump.